AI assistant
Sending…
Nautilus Biotechnology, Inc. — Director's Dealing 2021
Aug 13, 2021
34183_dirs_2021-08-13_8663a257-a54f-4618-9d56-ffe37a322029.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-08-13
Reporting Person: Murphy Matthew B. (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-13 | Common Stock | P | 5000 | $7.5613 | Acquired | 34140 | Indirect |
Footnotes
F1: Shares held by the Murphy Family Trust. The Reporting Person is the Trustee of the Murphy Family Trust.